The word “peptide” is doing too much work

Let’s start with the simplest truth.

A peptide is just a chain of amino acids—like pearls on a necklace. That’s it. Nothing mystical. Nothing magical.

However, structure matters. Sequence matters. Biology cares deeply about both.

Because of that, some peptides are extraordinarily powerful. Others are biologically interesting. And a growing number are simply… marketed.

That last category is where things get messy.

Before the hype, there was a miracle

Now rewind to a hospital ward in Toronto in the early 1920s.

Children with diabetes were dying. Not slowly improving. Not plateauing. Dying.

Then Frederick Banting and Charles Best walked in with something crude and experimental.

Insulin.

They injected it.

The children woke up.

Not metaphorically. Not in a graph. They woke up. Families watched death reverse in real time.

That is what a peptide can do when it actually works.

Then came the desert and the lizard

Fast forward a few decades.

Out in the Southwest—near where I started my first job as a bariatric surgeon in Phoenix—lives the Gila monster. Not exactly a creature you expect to change medicine.

Yet inside its venom was a peptide that led, eventually, to drugs like:

Semaglutide

That discovery didn’t go straight to Instagram.

Instead, it went through:

receptor biology
pharmacology
clinical trials
outcomes research

And the results were real:

lower blood sugar
meaningful weight loss
reduced cardiovascular risk

So yes, peptides can be extraordinary.

But only when the science is finished.

And then we lost the plot

Now, enter the modern peptide market.

Suddenly, everything is a peptide. Everything promises:

healing
recovery
fat loss
anti-aging

You’ve seen the names:

BPC-157
TB-500
CJC-1295
Ipamorelin
MOTS-c
AOD-9604

Meanwhile, they are sold in places that should make you pause immediately.

Gyms.

Wellness clinics.

Online “research chemical” shops.

Rarely, if ever, through the same channels as actual medicine.

BPC-157: the peptide that does everything… on paper

Start with the most famous one.

BPC-157 is marketed as a cure-all:

tendon healing
gut repair
anti-inflammatory
accelerated recovery

The claims are sweeping. The confidence is impressive.

But then you look at the evidence.

Animal studies? Yes.

Human randomized trials? No.

Long-term safety? Also no.

That gap matters.

Because when something claims to stimulate healing broadly, it raises an uncomfortable question:

What else might it stimulate?

The answer, at this point, is simple.

We don’t know.

TB-500: recovery without receipts

Next comes TB-500.

It is sold as a recovery peptide. It promises faster healing and improved flexibility.

The biology is plausible. The mechanism sounds reasonable.

Yet human evidence for those claims is lacking.

Even so, it thrives in:

bodybuilding circles
performance clinics
online forums

In other words, environments where anecdote travels faster than data.

Hormone peptides: changing numbers vs. changing outcomes

Now we get to the hormone crowd.

CJC-1295 and Ipamorelin are sold as a stack. They stimulate growth hormone release.

That part is real.

What comes next is not.

Because increasing a hormone level is not the same as improving health.

We do not have strong evidence for:

long-term outcomes
safety over years
meaningful clinical benefits

Still, they are marketed as anti-aging therapies.

That leap—from signal to certainty—is where the trouble begins.

Melanotan II: the one that proves the rule

Melanotan II is different.

It actually does something.

It increases pigmentation. It affects melanocortin receptors.

And with that comes:

nausea
blood pressure changes
mole darkening
documented toxicity

So here is the lesson.

When a peptide truly works, you don’t get silence. You get side effects.

The absence of side effects in marketing should never reassure you.

It should make you suspicious.

AOD-9604 and MOTS-c: the fantasy layer

At the far end of the spectrum are peptides like AOD-9604 and MOTS-c.

They promise:

targeted fat loss
exercise-like metabolic effects
longevity

The evidence?

Mostly cells and animals.

Yet they are already being sold, injected, and promoted.

At this point, we are not even pretending to wait for human data.

Where these actually come from

Now let’s talk about the vial.

Because this is where things shift from questionable to concerning.

Many of these peptides are:

manufactured overseas
shipped in bulk
repackaged
relabeled

They are often sold as:

“research chemicals”
“wellness therapies”

Independent testing has found:

incorrect dosing
contamination
inconsistent purity

So when someone says they are taking a specific peptide, the real answer is uncertain.

They hope they are.

Why this is suddenly in the news

Recently, Robert F. Kennedy Jr. has pushed to expand access to peptides restricted by the FDA.

The argument is framed as freedom.

The FDA’s concern is simpler:

lack of safety data
risk of contamination
unknown long-term effects

In other words, we do not yet know enough to call these safe.

That is not obstruction.

That is the job.

GLP-1: the difference data makes

Now compare all of that to GLP-1 drugs.

They don’t just sound scientific.

They are scientific.

They:

improve blood sugar
reduce weight
lower cardiovascular risk

Most importantly, they do this consistently, predictably, and measurably.

That is what happens when research goes the distance.

The bottom line

Peptides are not the problem.

Peptides gave us insulin.

Peptides gave us GLP-1.

At their best, they are among the most elegant tools in medicine.

But the current peptide market is not built on finished science.

Instead, it is built on possibility, dressed up as certainty.

And that difference matters.

Because the gap between “interesting biology” and “safe, effective therapy” is where patients get hurt.

Final thought

The difference between a child waking up in a Toronto hospital…

and a vial purchased online…

is not the molecule.

It is the evidence.